리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 06월
페이지 정보:영문 372 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 급성 근긴장이상 시장은 2030년까지 1억 3,220만 달러에 이를 전망
2024년에 1억 1,330만 달러로 추정되는 급성 근긴장이상 세계 시장은 2030년에는 1억 3,220만 달러에 이르고, 분석 기간인 2024-2030년 CAGR은 2.6%를 보일 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 항콜린제는 CAGR 3.0%를 나타내고, 분석 기간 종료시에는 8,160만 달러에 이를 것으로 예측됩니다. 벤조디아제핀계 약제 부문의 성장률은 분석 기간중 CAGR 2.1%로 추정됩니다.
미국 시장은 3,090만 달러로 추정, 중국은 CAGR 5.1%로 성장 예측
미국의 급성 근긴장이상 시장은 2024년에 3,090만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 분석 기간인 2024-2030년간 CAGR 5.1%로 2030년까지 2,560만 달러 규모에 이를 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 0.9%와 2.0%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 1.4%를 보일 전망입니다.
세계의 급성 근긴장이상 시장 - 주요 동향과 촉진요인 정리
급성 근긴장이상이 신경과와 응급의료 현장에서 임상적으로 주목받는 이유는 무엇일까?
급성 근긴장이상은 불수의적인 근육 수축, 비정상적인 자세, 반복적인 운동을 특징으로 하는 돌발성 운동 장애로, 특히 항정신병제물이나 구토억제제와 같은 특정 약물의 부작용으로 유발되는 경우가 많습니다. 대부분의 경우 가역적이지만, 이 병태는 고통스럽고 쇠약하게 만들 수 있기 때문에 빠른 인식과 표적화된 개입이 필요합니다. 약물에 의한 운동장애가 임상적으로 강조되면서 신경과와 응급의학 분야에서 급성 근긴장이상증에 대한 관심이 높아지고 있습니다.
정신과, 종양학, 소화기내과 영역에서 폴리파마시가 증가함에 따라 이질성 근긴장이상증의 위험도 증가하고 있습니다. 진단적 주의와 약물감시 프로토콜의 개선으로 더 많은 사례를 조기에 발견할 수 있게 되면서, 즉각적인 치료 솔루션과 표준화된 임상 관리 경로에 대한 요구가 증가하고 있습니다.
급성 디스토니아를 보다 효과적으로 관리하기 위해 치료법과 진단 프로토콜은 어떻게 진화하고 있는가?
급성 근긴장이상증의 1차 치료는 일반적으로 벤조트로핀이나 디펜히드라민과 같은 항콜린제를 정맥 또는 근육 내로 투여하여 증상을 빠르게 호전시키는 것입니다. 벤조디아제핀계 약물도 중증이나 내성이 있는 경우 보조적으로 사용됩니다. 조기 개입과 약물 중단을 위한 임상 가이드라인의 등장은 재발 위험을 줄이고 환자의 예후를 개선하는 데 도움이 되고 있습니다.
신경 영상 및 유전자 검사의 확대 등 감별 진단의 발전으로 급성 근긴장이상증과 다른 추체외로 증후군 및 신경근 질환과의 감별이 향상되고 있습니다. 한편, 디지털 도구와 웨어러블 기술은 입원 및 외래 환자 치료 모델 모두에서 실시간 증상 추적 및 원격 신경학적 평가를 지원하기 위해 시범적으로 도입되고 있습니다.
급성 근긴장이상증 관리 수요를 주도하는 환자 집단과 의료 환경은 무엇인가?
고강도 항정신병 약물을 복용하는 환자, 청소년 및 젊은 성인, 화학요법을 받는 환자, 도파민 길항제를 포함한 구토 방지 요법을 받는 환자 등 고위험군에 속합니다. 급성 디스토니아는 정신과 병동, 응급실, 종양학 클리닉에서 자주 발생하며, 종종 초기 약물 부작용으로 나타납니다. 예측할 수 없는 발병으로 인해 다양한 의료 현장에서의 대비가 필수적입니다.
북미와 유럽은 항정신병제물 처방률이 높고 부작용 보고 체계가 잘 갖추어져 있어 진단과 치료 측면에서 주요 지역입니다. 아시아태평양과 라틴아메리카에서는 정신 건강에 대한 인식이 높아지고 항정신병제물의 사용량이 증가하면서 급성 디스토니아에 대한 인식이 개선되고 있지만, 과소보고와 진단 지연이 여전히 만연해 있습니다.
인식 제고 캠페인, 임상 교육, 약물 관리는 시장 전망에 어떤 영향을 미쳤는가?
임상의를 대상으로 한錐?外路性 부작용에 대한 교육 노력은 특히 응급의료 및 정신과 의료에서 급성 근긴장이상증의 조기 발견 및 조기 대응을 향상시키고 있습니다. 지속적인 의학 교육(CME) 프로그램, 전자의무기록을 통한 경고, 약물 조정 프로토콜은 고위험군 처방에 플래그를 표시하고 부작용을 예방하는 데 사용되고 있습니다. 또한, 의약품 스튜어드십 프로그램을 통해 도파민 차단제 투여 시작 시 용량 증량 및 모니터링이 권장되고 있습니다.
제약회사와 보건당국은 근긴장이상증의 위험을 줄이기 위해 보다 명확한 라벨링, 부작용 추적, 시판 후 조사 등에 집중하고 있습니다. 이러한 조치들은 근긴장이상증 관리에 있어 보다 적극적이고 예방적인 접근 방식에 기여하고 있습니다. 인지도가 높아짐에 따라, 지지요법 시장에서는 개선된 제제 제공과 새로운 치료법 진입의 기회가 나타나고 있습니다.
급성 디스토니아 시장의 성장을 가속하는 요인은 무엇인가?
급성 근긴장이상증 시장은 약물감시 강화, 항정신병제물 및 구토억제제 사용률 증가, 진단 프레임워크 강화에 따라 진화하고 있습니다. 주요 성장 촉진요인으로는 의료 전문가들의 인식 증가, 신속한 치료 개입의 필요성, 정신과 및 종양학 의료에 대한 운동장애 스크리닝의 광범위한 통합 등을 들 수 있습니다. 환자 안전과 약물 모니터링이 중심적인 역할을 수행함에 따라 급성 근긴장이상증 관리에 대한 수요도 증가할 것으로 예측됩니다.
향후 시장 개척은 치료 프로토콜, 위험 감소 전략, 조기 진단 도구를 일상적인 진료 워크플로우에 얼마나 효과적으로 통합할 수 있는지에 달려 있습니다. 약물로 인한 운동장애가 보다 광범위한 신경학적 치료에서 인식됨에 따라, 급성 근긴장이상증은 약리학적 안전성과 맞춤 치료 경로를 촉진하는 중요한 접점이 될 수 있습니다.
부문
약제 클래스(항콜린제, 벤조디아제핀계 약제, 기타 약제 클래스별);연령층(소아, 성인);유통 채널(병원 약국, 소매 약국, 온라인 약국)
조사 대상 기업 예(총 42개사)
AbbVie Inc.
Amar Healthcare
Amneal Pharmaceuticals LLC
Aurobindo Pharma Ltd.
Bausch Health Companies, Inc.
Bayer Healthcare
Boston Scientific Corporation
China Shineway Pharmaceutical Group
Eisai Co., Ltd.
F. Hoffmann-La Roche Ltd
Fresenius Kabi
Ipsen Pharma
Johnson & Johnson
Mallinckrodt Pharmaceuticals
Medytox Inc.
Merck & Co., Inc.
Merz Pharmaceuticals GmbH
Novartis AG
PAI Pharma
Pfizer Inc.
관세 영향 계수
Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 수익원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.
Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사했습니다.
Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.
2025년 4월: 협상 단계
이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.
2025년 7월: 최종 관세 재설정
고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.
상호 및 양자 간 무역과 관세의 영향 분석 :
미국 <>& 중국 <>& 멕시코 <>& 캐나다 <>&EU <>& 일본 <>& 인도 <>& 기타 176개국
업계 최고의 이코노미스트: Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트를 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트(UAE)
기타 중동
아프리카
제4장 경쟁
LSH
영문 목차
영문목차
Global Acute Dystonia Market to Reach US$132.2 Million by 2030
The global market for Acute Dystonia estimated at US$113.3 Million in the year 2024, is expected to reach US$132.2 Million by 2030, growing at a CAGR of 2.6% over the analysis period 2024-2030. Anticholinergic Agents, one of the segments analyzed in the report, is expected to record a 3.0% CAGR and reach US$81.6 Million by the end of the analysis period. Growth in the Benzodiazepines segment is estimated at 2.1% CAGR over the analysis period.
The U.S. Market is Estimated at US$30.9 Million While China is Forecast to Grow at 5.1% CAGR
The Acute Dystonia market in the U.S. is estimated at US$30.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$25.6 Million by the year 2030 trailing a CAGR of 5.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 2.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.
Global Acute Dystonia Market - Key Trends & Drivers Summarized
Why Is Acute Dystonia Gaining Greater Clinical Attention Across Neurology and Emergency Care Settings?
Acute dystonia is a sudden-onset movement disorder characterized by involuntary muscle contractions, abnormal postures, and repetitive movements-typically triggered as an adverse reaction to certain medications, particularly antipsychotics and antiemetics. While often reversible, the condition can be distressing and potentially debilitating, necessitating prompt recognition and targeted intervention. The rising clinical emphasis on drug-induced movement disorders is bringing acute dystonia into sharper focus within both neurology and emergency medicine.
As polypharmacy increases across psychiatric, oncology, and gastroenterology domains, so too does the risk of iatrogenic dystonia. With improved diagnostic vigilance and pharmacovigilance protocols, more cases are being identified early, leading to increased demand for rapid-acting therapeutic solutions and standardized clinical management pathways.
How Are Treatment Modalities and Diagnostic Protocols Evolving to Manage Acute Dystonia More Effectively?
First-line treatment for acute dystonia typically includes anticholinergic agents such as benztropine or diphenhydramine, administered intravenously or intramuscularly for rapid symptom resolution. Benzodiazepines may also be used as adjuncts in more severe or resistant cases. The emergence of clinical guidelines for early intervention and drug discontinuation is helping reduce recurrence risk and improve patient outcomes.
Advancements in differential diagnosis, including expanded use of neuroimaging and genetic testing, are improving the distinction between acute dystonia and other extrapyramidal syndromes or neuromuscular disorders. Meanwhile, digital tools and wearable technologies are being piloted to aid real-time symptom tracking and remote neurological assessment in both inpatient and outpatient care models.
Which Patient Populations and Healthcare Environments Are Driving Demand for Acute Dystonia Management?
High-risk populations include individuals receiving high-potency antipsychotics, adolescents and young adults, and patients undergoing chemotherapy or anti-nausea regimens involving dopamine antagonists. Acute dystonia is frequently encountered in psychiatric wards, emergency departments, and oncology clinics, often as an early adverse drug reaction. Its unpredictable onset makes preparedness essential across diverse care settings.
North America and Europe, with high psychotropic prescription rates and structured adverse event reporting systems, are leading regions in terms of diagnosis and treatment. In Asia-Pacific and Latin America, rising mental health awareness and increasing antipsychotic usage are contributing to greater recognition of acute dystonia, although underreporting and diagnostic delays remain prevalent.
How Are Awareness Campaigns, Clinical Training, and Pharmaceutical Stewardship Impacting the Market Outlook?
Efforts to educate clinicians about extrapyramidal side effects-particularly in emergency and psychiatric care-are improving early identification and response to acute dystonia. Continuing medical education (CME) programs, electronic medical record alerts, and medication reconciliation protocols are being used to flag high-risk prescriptions and prevent adverse events. Pharmaceutical stewardship initiatives are also encouraging dose titration and monitoring when initiating dopamine-blocking agents.
Drug manufacturers and health authorities are focusing on clearer labelling, adverse reaction tracking, and post-marketing surveillance to mitigate dystonia risk. These measures are contributing to a more proactive and preventive approach in managing the condition. As awareness grows, opportunities for improved formulation delivery and new therapeutic entrants are beginning to surface within the supportive care market.
What Are the Factors Driving Growth in the Acute Dystonia Market?
The acute dystonia market is evolving in response to increased pharmacovigilance, higher rates of antipsychotic and antiemetic use, and stronger diagnostic frameworks. Key growth drivers include rising awareness among healthcare professionals, the need for rapid-onset therapeutic interventions, and broader integration of movement disorder screening into psychiatric and oncologic care. As patient safety and medication monitoring take center stage, demand for acute dystonia management is expected to intensify.
Looking ahead, market development will depend on how effectively treatment protocols, risk mitigation strategies, and early diagnostic tools can be embedded into routine clinical workflows. As drug-induced movement disorders gain visibility within broader neurological care, could acute dystonia become a key touchpoint in advancing pharmacological safety and personalized treatment pathways?
SCOPE OF STUDY:
The report analyzes the Acute Dystonia market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Drug Class (Anticholinergic Agents, Benzodiazepines, Other Drug Classes); Age Group (Children, Adult); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 42 Featured) -
AbbVie Inc.
Amar Healthcare
Amneal Pharmaceuticals LLC
Aurobindo Pharma Ltd.
Bausch Health Companies, Inc.
Bayer Healthcare
Boston Scientific Corporation
China Shineway Pharmaceutical Group
Eisai Co., Ltd.
F. Hoffmann-La Roche Ltd
Fresenius Kabi
Ipsen Pharma
Johnson & Johnson
Mallinckrodt Pharmaceuticals
Medytox Inc.
Merck & Co., Inc.
Merz Pharmaceuticals GmbH
Novartis AG
PAI Pharma
Pfizer Inc.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.
We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.
As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.
To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!
APRIL 2025: NEGOTIATION PHASE
Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.
JULY 2025 FINAL TARIFF RESET
Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.
Reciprocal and Bilateral Trade & Tariff Impact Analyses:
USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.
Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.
COMPLIMENTARY PREVIEW
Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Acute Dystonia - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Incidence of Drug-Induced Movement Disorders Throws the Spotlight on Acute Dystonia Treatment Demand
Growth in Use of Antipsychotic Medications Spurs Market for Dystonia Mitigating Therapies
Increasing Clinical Recognition and Reporting Enhances Diagnosis and Therapeutic Response Rates
Advances in Neurology and Movement Disorder Research Strengthen the Business Case for Targeted Treatments
Surge in Emergency Room Visits Due to Dystonic Reactions Bodes Well for Fast-Acting Therapeutics
Growing Awareness Among Healthcare Providers Drives Early Detection and Intervention Rates
Shift Toward Personalized Neurology Care Encourages Development of Patient-Specific Dystonia Protocols
Increasing Availability of Intramuscular Anticholinergics and Benzodiazepines Supports Emergency Dystonia Management
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Acute Dystonia Market Analysis of Annual Sales in US$ for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Acute Dystonia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Acute Dystonia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for Acute Dystonia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Anticholinergic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Anticholinergic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for Anticholinergic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Benzodiazepines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Benzodiazepines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for Benzodiazepines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Children by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Children by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 16: World 15-Year Perspective for Children by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 19: World 15-Year Perspective for Adult by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 22: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 25: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 28: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Acute Dystonia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 29: USA Recent Past, Current & Future Analysis for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 30: USA Historic Review for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 31: USA 15-Year Perspective for Acute Dystonia by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents, Benzodiazepines and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 32: USA Recent Past, Current & Future Analysis for Acute Dystonia by Age Group - Children and Adult - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 33: USA Historic Review for Acute Dystonia by Age Group - Children and Adult Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 34: USA 15-Year Perspective for Acute Dystonia by Age Group - Percentage Breakdown of Value Sales for Children and Adult for the Years 2015, 2025 & 2030
TABLE 35: USA Recent Past, Current & Future Analysis for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 36: USA Historic Review for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 37: USA 15-Year Perspective for Acute Dystonia by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
CANADA
TABLE 38: Canada Recent Past, Current & Future Analysis for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 39: Canada Historic Review for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 40: Canada 15-Year Perspective for Acute Dystonia by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents, Benzodiazepines and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 41: Canada Recent Past, Current & Future Analysis for Acute Dystonia by Age Group - Children and Adult - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 42: Canada Historic Review for Acute Dystonia by Age Group - Children and Adult Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 43: Canada 15-Year Perspective for Acute Dystonia by Age Group - Percentage Breakdown of Value Sales for Children and Adult for the Years 2015, 2025 & 2030
TABLE 44: Canada Recent Past, Current & Future Analysis for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 45: Canada Historic Review for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 46: Canada 15-Year Perspective for Acute Dystonia by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
JAPAN
Acute Dystonia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 47: Japan Recent Past, Current & Future Analysis for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 48: Japan Historic Review for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 49: Japan 15-Year Perspective for Acute Dystonia by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents, Benzodiazepines and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 50: Japan Recent Past, Current & Future Analysis for Acute Dystonia by Age Group - Children and Adult - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 51: Japan Historic Review for Acute Dystonia by Age Group - Children and Adult Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 52: Japan 15-Year Perspective for Acute Dystonia by Age Group - Percentage Breakdown of Value Sales for Children and Adult for the Years 2015, 2025 & 2030
TABLE 53: Japan Recent Past, Current & Future Analysis for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 54: Japan Historic Review for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 55: Japan 15-Year Perspective for Acute Dystonia by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
CHINA
Acute Dystonia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 56: China Recent Past, Current & Future Analysis for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 57: China Historic Review for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 58: China 15-Year Perspective for Acute Dystonia by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents, Benzodiazepines and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 59: China Recent Past, Current & Future Analysis for Acute Dystonia by Age Group - Children and Adult - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 60: China Historic Review for Acute Dystonia by Age Group - Children and Adult Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 61: China 15-Year Perspective for Acute Dystonia by Age Group - Percentage Breakdown of Value Sales for Children and Adult for the Years 2015, 2025 & 2030
TABLE 62: China Recent Past, Current & Future Analysis for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 63: China Historic Review for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 64: China 15-Year Perspective for Acute Dystonia by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
EUROPE
Acute Dystonia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 65: Europe Recent Past, Current & Future Analysis for Acute Dystonia by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 66: Europe Historic Review for Acute Dystonia by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 67: Europe 15-Year Perspective for Acute Dystonia by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 68: Europe Recent Past, Current & Future Analysis for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 69: Europe Historic Review for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 70: Europe 15-Year Perspective for Acute Dystonia by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents, Benzodiazepines and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 71: Europe Recent Past, Current & Future Analysis for Acute Dystonia by Age Group - Children and Adult - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 72: Europe Historic Review for Acute Dystonia by Age Group - Children and Adult Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 73: Europe 15-Year Perspective for Acute Dystonia by Age Group - Percentage Breakdown of Value Sales for Children and Adult for the Years 2015, 2025 & 2030
TABLE 74: Europe Recent Past, Current & Future Analysis for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 75: Europe Historic Review for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 76: Europe 15-Year Perspective for Acute Dystonia by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
FRANCE
Acute Dystonia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 77: France Recent Past, Current & Future Analysis for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 78: France Historic Review for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 79: France 15-Year Perspective for Acute Dystonia by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents, Benzodiazepines and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 80: France Recent Past, Current & Future Analysis for Acute Dystonia by Age Group - Children and Adult - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 81: France Historic Review for Acute Dystonia by Age Group - Children and Adult Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 82: France 15-Year Perspective for Acute Dystonia by Age Group - Percentage Breakdown of Value Sales for Children and Adult for the Years 2015, 2025 & 2030
TABLE 83: France Recent Past, Current & Future Analysis for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 84: France Historic Review for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 85: France 15-Year Perspective for Acute Dystonia by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
GERMANY
Acute Dystonia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 86: Germany Recent Past, Current & Future Analysis for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 87: Germany Historic Review for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 88: Germany 15-Year Perspective for Acute Dystonia by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents, Benzodiazepines and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 89: Germany Recent Past, Current & Future Analysis for Acute Dystonia by Age Group - Children and Adult - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 90: Germany Historic Review for Acute Dystonia by Age Group - Children and Adult Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 91: Germany 15-Year Perspective for Acute Dystonia by Age Group - Percentage Breakdown of Value Sales for Children and Adult for the Years 2015, 2025 & 2030
TABLE 92: Germany Recent Past, Current & Future Analysis for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 93: Germany Historic Review for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 94: Germany 15-Year Perspective for Acute Dystonia by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
ITALY
TABLE 95: Italy Recent Past, Current & Future Analysis for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 96: Italy Historic Review for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 97: Italy 15-Year Perspective for Acute Dystonia by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents, Benzodiazepines and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 98: Italy Recent Past, Current & Future Analysis for Acute Dystonia by Age Group - Children and Adult - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 99: Italy Historic Review for Acute Dystonia by Age Group - Children and Adult Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 100: Italy 15-Year Perspective for Acute Dystonia by Age Group - Percentage Breakdown of Value Sales for Children and Adult for the Years 2015, 2025 & 2030
TABLE 101: Italy Recent Past, Current & Future Analysis for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 102: Italy Historic Review for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 103: Italy 15-Year Perspective for Acute Dystonia by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
UNITED KINGDOM
Acute Dystonia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 104: UK Recent Past, Current & Future Analysis for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 105: UK Historic Review for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 106: UK 15-Year Perspective for Acute Dystonia by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents, Benzodiazepines and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 107: UK Recent Past, Current & Future Analysis for Acute Dystonia by Age Group - Children and Adult - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 108: UK Historic Review for Acute Dystonia by Age Group - Children and Adult Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 109: UK 15-Year Perspective for Acute Dystonia by Age Group - Percentage Breakdown of Value Sales for Children and Adult for the Years 2015, 2025 & 2030
TABLE 110: UK Recent Past, Current & Future Analysis for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 111: UK Historic Review for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 112: UK 15-Year Perspective for Acute Dystonia by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
SPAIN
TABLE 113: Spain Recent Past, Current & Future Analysis for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 114: Spain Historic Review for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 115: Spain 15-Year Perspective for Acute Dystonia by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents, Benzodiazepines and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 116: Spain Recent Past, Current & Future Analysis for Acute Dystonia by Age Group - Children and Adult - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 117: Spain Historic Review for Acute Dystonia by Age Group - Children and Adult Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 118: Spain 15-Year Perspective for Acute Dystonia by Age Group - Percentage Breakdown of Value Sales for Children and Adult for the Years 2015, 2025 & 2030
TABLE 119: Spain Recent Past, Current & Future Analysis for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 120: Spain Historic Review for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 121: Spain 15-Year Perspective for Acute Dystonia by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
RUSSIA
TABLE 122: Russia Recent Past, Current & Future Analysis for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 123: Russia Historic Review for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 124: Russia 15-Year Perspective for Acute Dystonia by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents, Benzodiazepines and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 125: Russia Recent Past, Current & Future Analysis for Acute Dystonia by Age Group - Children and Adult - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 126: Russia Historic Review for Acute Dystonia by Age Group - Children and Adult Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 127: Russia 15-Year Perspective for Acute Dystonia by Age Group - Percentage Breakdown of Value Sales for Children and Adult for the Years 2015, 2025 & 2030
TABLE 128: Russia Recent Past, Current & Future Analysis for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 129: Russia Historic Review for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 130: Russia 15-Year Perspective for Acute Dystonia by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 132: Rest of Europe Historic Review for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 133: Rest of Europe 15-Year Perspective for Acute Dystonia by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents, Benzodiazepines and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Acute Dystonia by Age Group - Children and Adult - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 135: Rest of Europe Historic Review for Acute Dystonia by Age Group - Children and Adult Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 136: Rest of Europe 15-Year Perspective for Acute Dystonia by Age Group - Percentage Breakdown of Value Sales for Children and Adult for the Years 2015, 2025 & 2030
TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 138: Rest of Europe Historic Review for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 139: Rest of Europe 15-Year Perspective for Acute Dystonia by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Acute Dystonia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Acute Dystonia by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 141: Asia-Pacific Historic Review for Acute Dystonia by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 142: Asia-Pacific 15-Year Perspective for Acute Dystonia by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 144: Asia-Pacific Historic Review for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 145: Asia-Pacific 15-Year Perspective for Acute Dystonia by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents, Benzodiazepines and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Acute Dystonia by Age Group - Children and Adult - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 147: Asia-Pacific Historic Review for Acute Dystonia by Age Group - Children and Adult Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 148: Asia-Pacific 15-Year Perspective for Acute Dystonia by Age Group - Percentage Breakdown of Value Sales for Children and Adult for the Years 2015, 2025 & 2030
TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 150: Asia-Pacific Historic Review for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 151: Asia-Pacific 15-Year Perspective for Acute Dystonia by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
AUSTRALIA
Acute Dystonia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 152: Australia Recent Past, Current & Future Analysis for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 153: Australia Historic Review for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 154: Australia 15-Year Perspective for Acute Dystonia by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents, Benzodiazepines and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 155: Australia Recent Past, Current & Future Analysis for Acute Dystonia by Age Group - Children and Adult - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 156: Australia Historic Review for Acute Dystonia by Age Group - Children and Adult Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 157: Australia 15-Year Perspective for Acute Dystonia by Age Group - Percentage Breakdown of Value Sales for Children and Adult for the Years 2015, 2025 & 2030
TABLE 158: Australia Recent Past, Current & Future Analysis for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 159: Australia Historic Review for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 160: Australia 15-Year Perspective for Acute Dystonia by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
INDIA
Acute Dystonia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 161: India Recent Past, Current & Future Analysis for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 162: India Historic Review for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 163: India 15-Year Perspective for Acute Dystonia by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents, Benzodiazepines and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 164: India Recent Past, Current & Future Analysis for Acute Dystonia by Age Group - Children and Adult - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 165: India Historic Review for Acute Dystonia by Age Group - Children and Adult Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 166: India 15-Year Perspective for Acute Dystonia by Age Group - Percentage Breakdown of Value Sales for Children and Adult for the Years 2015, 2025 & 2030
TABLE 167: India Recent Past, Current & Future Analysis for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 168: India Historic Review for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 169: India 15-Year Perspective for Acute Dystonia by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
SOUTH KOREA
TABLE 170: South Korea Recent Past, Current & Future Analysis for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 171: South Korea Historic Review for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 172: South Korea 15-Year Perspective for Acute Dystonia by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents, Benzodiazepines and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 173: South Korea Recent Past, Current & Future Analysis for Acute Dystonia by Age Group - Children and Adult - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 174: South Korea Historic Review for Acute Dystonia by Age Group - Children and Adult Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 175: South Korea 15-Year Perspective for Acute Dystonia by Age Group - Percentage Breakdown of Value Sales for Children and Adult for the Years 2015, 2025 & 2030
TABLE 176: South Korea Recent Past, Current & Future Analysis for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 177: South Korea Historic Review for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 178: South Korea 15-Year Perspective for Acute Dystonia by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 180: Rest of Asia-Pacific Historic Review for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Acute Dystonia by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents, Benzodiazepines and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Dystonia by Age Group - Children and Adult - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 183: Rest of Asia-Pacific Historic Review for Acute Dystonia by Age Group - Children and Adult Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Acute Dystonia by Age Group - Percentage Breakdown of Value Sales for Children and Adult for the Years 2015, 2025 & 2030
TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 186: Rest of Asia-Pacific Historic Review for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Acute Dystonia by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
LATIN AMERICA
Acute Dystonia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 188: Latin America Recent Past, Current & Future Analysis for Acute Dystonia by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 189: Latin America Historic Review for Acute Dystonia by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 190: Latin America 15-Year Perspective for Acute Dystonia by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
TABLE 191: Latin America Recent Past, Current & Future Analysis for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 192: Latin America Historic Review for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 193: Latin America 15-Year Perspective for Acute Dystonia by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents, Benzodiazepines and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 194: Latin America Recent Past, Current & Future Analysis for Acute Dystonia by Age Group - Children and Adult - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 195: Latin America Historic Review for Acute Dystonia by Age Group - Children and Adult Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 196: Latin America 15-Year Perspective for Acute Dystonia by Age Group - Percentage Breakdown of Value Sales for Children and Adult for the Years 2015, 2025 & 2030
TABLE 197: Latin America Recent Past, Current & Future Analysis for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 198: Latin America Historic Review for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 199: Latin America 15-Year Perspective for Acute Dystonia by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
ARGENTINA
TABLE 200: Argentina Recent Past, Current & Future Analysis for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 201: Argentina Historic Review for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 202: Argentina 15-Year Perspective for Acute Dystonia by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents, Benzodiazepines and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 203: Argentina Recent Past, Current & Future Analysis for Acute Dystonia by Age Group - Children and Adult - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 204: Argentina Historic Review for Acute Dystonia by Age Group - Children and Adult Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 205: Argentina 15-Year Perspective for Acute Dystonia by Age Group - Percentage Breakdown of Value Sales for Children and Adult for the Years 2015, 2025 & 2030
TABLE 206: Argentina Recent Past, Current & Future Analysis for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 207: Argentina Historic Review for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 208: Argentina 15-Year Perspective for Acute Dystonia by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
BRAZIL
TABLE 209: Brazil Recent Past, Current & Future Analysis for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 210: Brazil Historic Review for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 211: Brazil 15-Year Perspective for Acute Dystonia by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents, Benzodiazepines and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 212: Brazil Recent Past, Current & Future Analysis for Acute Dystonia by Age Group - Children and Adult - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 213: Brazil Historic Review for Acute Dystonia by Age Group - Children and Adult Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 214: Brazil 15-Year Perspective for Acute Dystonia by Age Group - Percentage Breakdown of Value Sales for Children and Adult for the Years 2015, 2025 & 2030
TABLE 215: Brazil Recent Past, Current & Future Analysis for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 216: Brazil Historic Review for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 217: Brazil 15-Year Perspective for Acute Dystonia by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
MEXICO
TABLE 218: Mexico Recent Past, Current & Future Analysis for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 219: Mexico Historic Review for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 220: Mexico 15-Year Perspective for Acute Dystonia by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents, Benzodiazepines and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 221: Mexico Recent Past, Current & Future Analysis for Acute Dystonia by Age Group - Children and Adult - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 222: Mexico Historic Review for Acute Dystonia by Age Group - Children and Adult Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 223: Mexico 15-Year Perspective for Acute Dystonia by Age Group - Percentage Breakdown of Value Sales for Children and Adult for the Years 2015, 2025 & 2030
TABLE 224: Mexico Recent Past, Current & Future Analysis for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 225: Mexico Historic Review for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 226: Mexico 15-Year Perspective for Acute Dystonia by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 228: Rest of Latin America Historic Review for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 229: Rest of Latin America 15-Year Perspective for Acute Dystonia by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents, Benzodiazepines and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Acute Dystonia by Age Group - Children and Adult - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 231: Rest of Latin America Historic Review for Acute Dystonia by Age Group - Children and Adult Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 232: Rest of Latin America 15-Year Perspective for Acute Dystonia by Age Group - Percentage Breakdown of Value Sales for Children and Adult for the Years 2015, 2025 & 2030
TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 234: Rest of Latin America Historic Review for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 235: Rest of Latin America 15-Year Perspective for Acute Dystonia by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
MIDDLE EAST
Acute Dystonia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 236: Middle East Recent Past, Current & Future Analysis for Acute Dystonia by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 237: Middle East Historic Review for Acute Dystonia by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 238: Middle East 15-Year Perspective for Acute Dystonia by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
TABLE 239: Middle East Recent Past, Current & Future Analysis for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 240: Middle East Historic Review for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 241: Middle East 15-Year Perspective for Acute Dystonia by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents, Benzodiazepines and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 242: Middle East Recent Past, Current & Future Analysis for Acute Dystonia by Age Group - Children and Adult - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 243: Middle East Historic Review for Acute Dystonia by Age Group - Children and Adult Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 244: Middle East 15-Year Perspective for Acute Dystonia by Age Group - Percentage Breakdown of Value Sales for Children and Adult for the Years 2015, 2025 & 2030
TABLE 245: Middle East Recent Past, Current & Future Analysis for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 246: Middle East Historic Review for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 247: Middle East 15-Year Perspective for Acute Dystonia by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
IRAN
TABLE 248: Iran Recent Past, Current & Future Analysis for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 249: Iran Historic Review for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 250: Iran 15-Year Perspective for Acute Dystonia by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents, Benzodiazepines and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 251: Iran Recent Past, Current & Future Analysis for Acute Dystonia by Age Group - Children and Adult - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 252: Iran Historic Review for Acute Dystonia by Age Group - Children and Adult Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 253: Iran 15-Year Perspective for Acute Dystonia by Age Group - Percentage Breakdown of Value Sales for Children and Adult for the Years 2015, 2025 & 2030
TABLE 254: Iran Recent Past, Current & Future Analysis for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 255: Iran Historic Review for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 256: Iran 15-Year Perspective for Acute Dystonia by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
ISRAEL
TABLE 257: Israel Recent Past, Current & Future Analysis for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 258: Israel Historic Review for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 259: Israel 15-Year Perspective for Acute Dystonia by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents, Benzodiazepines and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 260: Israel Recent Past, Current & Future Analysis for Acute Dystonia by Age Group - Children and Adult - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 261: Israel Historic Review for Acute Dystonia by Age Group - Children and Adult Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 262: Israel 15-Year Perspective for Acute Dystonia by Age Group - Percentage Breakdown of Value Sales for Children and Adult for the Years 2015, 2025 & 2030
TABLE 263: Israel Recent Past, Current & Future Analysis for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 264: Israel Historic Review for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 265: Israel 15-Year Perspective for Acute Dystonia by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
SAUDI ARABIA
TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 267: Saudi Arabia Historic Review for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 268: Saudi Arabia 15-Year Perspective for Acute Dystonia by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents, Benzodiazepines and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Acute Dystonia by Age Group - Children and Adult - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 270: Saudi Arabia Historic Review for Acute Dystonia by Age Group - Children and Adult Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 271: Saudi Arabia 15-Year Perspective for Acute Dystonia by Age Group - Percentage Breakdown of Value Sales for Children and Adult for the Years 2015, 2025 & 2030
TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 273: Saudi Arabia Historic Review for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 274: Saudi Arabia 15-Year Perspective for Acute Dystonia by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 275: UAE Recent Past, Current & Future Analysis for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 276: UAE Historic Review for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 277: UAE 15-Year Perspective for Acute Dystonia by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents, Benzodiazepines and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 278: UAE Recent Past, Current & Future Analysis for Acute Dystonia by Age Group - Children and Adult - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 279: UAE Historic Review for Acute Dystonia by Age Group - Children and Adult Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 280: UAE 15-Year Perspective for Acute Dystonia by Age Group - Percentage Breakdown of Value Sales for Children and Adult for the Years 2015, 2025 & 2030
TABLE 281: UAE Recent Past, Current & Future Analysis for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 282: UAE Historic Review for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 283: UAE 15-Year Perspective for Acute Dystonia by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 285: Rest of Middle East Historic Review for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 286: Rest of Middle East 15-Year Perspective for Acute Dystonia by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents, Benzodiazepines and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Acute Dystonia by Age Group - Children and Adult - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 288: Rest of Middle East Historic Review for Acute Dystonia by Age Group - Children and Adult Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 289: Rest of Middle East 15-Year Perspective for Acute Dystonia by Age Group - Percentage Breakdown of Value Sales for Children and Adult for the Years 2015, 2025 & 2030
TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 291: Rest of Middle East Historic Review for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 292: Rest of Middle East 15-Year Perspective for Acute Dystonia by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
AFRICA
Acute Dystonia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 293: Africa Recent Past, Current & Future Analysis for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 294: Africa Historic Review for Acute Dystonia by Drug Class - Anticholinergic Agents, Benzodiazepines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 295: Africa 15-Year Perspective for Acute Dystonia by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents, Benzodiazepines and Other Drug Classes for the Years 2015, 2025 & 2030
TABLE 296: Africa Recent Past, Current & Future Analysis for Acute Dystonia by Age Group - Children and Adult - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 297: Africa Historic Review for Acute Dystonia by Age Group - Children and Adult Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 298: Africa 15-Year Perspective for Acute Dystonia by Age Group - Percentage Breakdown of Value Sales for Children and Adult for the Years 2015, 2025 & 2030
TABLE 299: Africa Recent Past, Current & Future Analysis for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 300: Africa Historic Review for Acute Dystonia by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
TABLE 301: Africa 15-Year Perspective for Acute Dystonia by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030